Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY10 | Q96PN6 | 5/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18622401 | 0.85 | ALDH1A1 (0.34) | NMT1HTTCHRM4 | |
| SCHEMBL21171659 | 0.84 | ADCY10 (0.36) | ADCY10NMT1HTTCHRM4 | |
| SCHEMBL21171808 | 0.82 | NMT1 (0.35) | ADCY10NMT1HTTCHRM4 | |
| SCHEMBL18646449 | 0.78 | ADCY10 (0.32) | ADCY10NMT1 | |
| SCHEMBL23116058 | 0.70 | ADORA2A (0.42) | NMT1HTT | |
| SCHEMBL13106183 | 0.70 | HSD11B1 (0.37) | ADCY10NMT1CHRM4 | |
| SCHEMBL24001986 | 0.67 | KDM4E (0.37) | HTT | |
| SCHEMBL13106181 | 0.65 | CHRM4 (0.35) | NMT1HTTCHRM4 | |
| SCHEMBL31537424 | 0.65 | — | — | |
| SCHEMBL13106159 | 0.64 | PARP1 (0.41) | CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026080-B | Pyrazolyl-substituted heteroaryl compounds and their use as medicaments | 勃林格殷格翰国际有限公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-3347353-B1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3347353-B1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| US-10155751-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-12-18 | — | — | US | disclosed |
| EP-3347353-A1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2018-07-18 | — | — | EP | disclosed |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INT (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INT (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INT (DE) | 2018-05-31 | — | — | US | disclosed |
| US-9845314-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRNGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-12-19 | — | — | US | disclosed |
| US-9845314-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRNGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-12-19 | — | — | US | disclosed |
| US-9845314-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRNGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-12-19 | — | — | US | disclosed |
| WO-2017042100-A1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017042100-A1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-16 | — | — | WO | disclosed |
| US-20170073333-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073333-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073333-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155751-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | HRH4, HRH3, HRH1 | ADCY10 2933/4885NMT1 3351/4885HTT 2971/4885 |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | HRH4, HRH2, HRH3 | ADCY10 3233/4885NMT1 3631/4885HTT 3034/4885 |
| US-20170073333-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | HRH4, HRH2, HRH3 | ADCY10 3233/4885NMT1 3631/4885HTT 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.